News Feature: Low Risk of Malignancy with Secukinumab Analysis of ongoing safety from the SEC drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, PsA or AS. https://t.co/tf1lWa03tF https://t.co/Ad1fOJZv4c